TOP 5 downloaded articles
Check out top downloaded articles.
ICFSR 2015: INTERNATIONAL CONFERENCE ON FRAILTY & SARCOPENIA RESEARCH THURSDAY - SATURDAY, APRIL 23-25, 2015 BOSTON, MA, USA
Abstracts
J Frailty Aging 2015;4(S1):19-108
Show summaryHide summaryNo summary available.
OPEN ACCESSICFSR: 8th International Conference on Frailty & Sarcopenia Research, March 1-3, 2018, Miami – USA
Poster, ONLINE EXCLUSIVE
J Frailty Aging 2018;7(S1):92-173
Show summaryHide summary
CITATION:
Poster (2018): ICFSR: 8th International Conference on Frailty and Sarcopenia Research, March 1-3, 2018, Miami – USA. The Journal of Frailty and Aging (JFA). http://dx.doi.org/10.14283/jfa.2018.4
THE GREEN TEA POLYPHENOL EPIGALLOCATECHIN-3-GALLATE (EGCG) ATTENUATES SKELETAL MUSCLE ATROPHY IN A RAT MODEL OF SARCOPENIA
B.M. Meador, K.A. Mirza, M. Tian, M.B. Skelding, L.A. Reaves, N.K. Edens, M.J. Tisdale, S.L. Pereira
J Frailty Aging 2015;4(4):209-215
Show summaryHide summaryObjective: Sarcopenia—the loss of muscle mass and functionality occurring with age—is a pervasive problem with few effective treatments beyond exercise. We examined the ability of the green tea catechin, epigallocatechin-3-gallate (EGCg), to impact muscle mass and the molecular pathway involved in muscle atrophy in a rat model of sarcopenia. Methods: 20-month-old Sprague-Dawley rats were treated for 8 weeks with control diet or control plus 200mg/kg body weight of EGCg diet. Results: EGCg-supplemented animals had significantly greater gastrocnemius muscle mass than the aged controls, and showed a trend for increased muscle fiber cross-sectional areas (CSA) (p=0.06). These changes were associated with significantly lower protein expressions of the intramuscular 19S and 20S proteasome subunits and the MuRF1 and MAFbx ubiquitin ligases in the EGCg-treated animals. Proteasome activity as determined by ‘Chymotrypsin-like’ enzyme activity was also significantly reduced by EGCg. Muscle mRNA expression of IL-15 and IGF-1 were significantly increased in the EGCg group vs. the aged controls. In comparison to younger adult animals (6 month), the protein expression of 19S, 20S, MuRF1, MAFbx, and myostatin were increased between approximately 4- and 12-fold in the aged controls, but only up to ~2-fold in the aged EGCg animals. Conclusions: EGCg supplementation was able to preserve muscle in sarcopenic rats, partly through attenuating protein degradation via the ubiquitin-proteasome pathway, together with increased expression of anabolic factors.
CITATION:
B.M. Meador ; K.A. Mirza ; M. Tian ; M.B. Skelding ; L.A. Reaves ; N.K. Edens ; M.J. Tisdale ; S.L. Pereira (2015): The green tea polyphenol Epigallocatechin-3-gallate (EGCg) attenuates skeletal muscle atrophy in a rat model of sarcopenia. The Journal of Frailty and Aging (JFA). http://dx.doi.org/10.14283/jfa.2015.58
PREDICTION OF COGNITIVE STATUS AND 5-YEAR SURVIVAL RATE FOR ELDERLY WITH CARDIOVASCULAR DISEASES: A CANADIAN STUDY OF HEALTH AND AGING SECONDARY DATA ANALYSIS
S. Pakzad, P. Bourque, N. Fallah
J Frailty Aging 2021;10(1)31-37
Show summaryHide summaryBackground: Given the important association between cardiovascular disease and cognitive decline, and their significant implications on frailty status, the contribution of neurocognitive frailty measure helping with the assessment of patient outcomes is dearly needed. Objectives: The present study examines the prognostic value of the Neurocognitive Frailty Index (NFI) in the elderly with cardiovascular disease. Design: Secondary analysis of the Canadian Study of Health and Aging (CSHA) dataset was used for prediction of 5-year cognitive changes. Setting: Community and institutional sample. Participants: Canadians aged 65 and over [Mean age: 80.4 years (SD=6.9; Range of 66-100)]. Measurement: Neurocognitive Frailty Index (NFI) and Modified Mini-Mental State (3MS) scores for cognitive functioning of all subjects at follow-up and mortality rate were measured. Results: The NFI mean score was 9.63 (SD = 6.04) and ranged from 0 to 33. This study demonstrated that the NFI was significantly associated with cognitive changes for subjects with heart disease and this correlation was a stronger predictor than age. Conclusion: The clinical relevance of this study is that our result supports the prognostic utility of the NFI tool in treatment planning for those with modifiable cardiovascular disease risk factors in the development of dementia.
CITATION:
S. Pakzad ; P. Bourque ; N. Fallah (2020): Prediction of Cognitive Status and 5-year Survival rate for Elderly with Cardiovascular Diseases: A Canadian Study of Health and Aging Secondary Data Analysis. The Journal of Frailty and Aging (JFA). http://dx.doi.org/10.14283/jfa.2020.21
COGNITIVE FUNCTION AND AMYLOID MARKER IN FRAIL OLDER ADULTS: THE COGFRAIL COHORT STUDY
S. Sourdet, G. Soriano, J. Delrieu, Z. Steinmeyer, S. Guyonnet, L. Saint-Aubert, P. Payoux, P.J. Ousset, A. Ghisolfi, B. Chicoulaa, S. Dardenne, T. Gemar, M. Baziard, F. Guerville, S. Andrieu, B. Vellas
J Frailty Aging 2021;10(2)160-167
Show summaryHide summaryBackground: Frailty and cognitive impairment are common manifestations of the ageing process and are closely related. But the mechanisms linking aging, physical frailty, and cognitive disorders, are complex and remain unclear. Objectives: We aim to explore the role of cerebral amyloid pathology, but also a range of nutritional, physical, biological or brain-aging marker in the development of cognitive frailty. Method: COGFRAIL study is a monocentric prospective study of frail older patients with an objective cognitive impairment (Clinical Dementia Rating Scale global score at 0.5 or 1). Three-hundred-and-twenty-one patients are followed up every 6 months, for 2 years. Clinical assessment at baseline and during follow-up included frailty, physical, mood, sensory, nutritional, and cognitive assessment (with a set of neuropsychological tests). Cerebral amyloid pathology is measured by amyloid Positron Emission Tomography (PET) or amyloid-β-1-42 level in cerebrospinal fluid. Brain magnetic resonance imaging, measurement of body composition using Dual X Ray Absorptiometry and blood sampling are performed. The main outcome of the study is to assess the prevalence of positive cerebral amyloid status according to amyloid PET or amyloid-β-1-42 level CSF. Secondary outcomes included biological, nutritional, MRI imaging, cognitive, clinical, physical and body composition markers to better understand the mechanisms of cognitive frailty. Perspective: COGFRAIL study will give the opportunity to better understand the link between Gerosciences, frailty, cognitive impairment, and Alzheimer’s disease, and to better characterize the physical and cognitive trajectories of frail older adults according to their amyloid status. Understanding the relationship between physical frailty and cognitive impairment is a prerequisite for the development of new interventions that could prevent and treat both conditions.
CITATION:
S. Sourdet ; G. Soriano ; J. Delrieu ; Z. Steinmeyer ; S. Guyonnet ; L. Saint-Aubert ; P. Payoux ; P.J. Ousset ; A. Ghisolfi ; B. Chicoulaa ; S. Dardenne ; T. Gemar ; M. Baziard ; F. Guerville ; S. Andrieu ; B. Vellas (2020): Cognitive function and amyloid marker in frail older adults: The COGFRAIL Cohort Study. The Journal of Frailty and Aging (JFA). http://dx.doi.org/10.14283/jfa.2020.57